Skip to main content
. Author manuscript; available in PMC: 2011 Oct 15.
Published in final edited form as: Transplantation. 2010 Oct 15;90(7):709–716. doi: 10.1097/TP.0b013e3181ed55d8

Figure 1. Diannexin accelerates the reversal of hyperglycemia following marginal islet mass transplantation.

Figure 1

Streptozotocin-induced diabetic BALB/c mice received a marginal mass of syngeneic islets under the kidney capsule. Diannexin was given to donors, added to islet isolation reagents, and injected into recipients on days 0-4 post-transplantation. (A) Reversal of diabetes, as defined by blood glucose levels <200mg/dl on three consecutive measurements, after marginal islet mass transplantation in Diannexin treatment vs. control. Two-tailed P values calculated using the log rank test. (B) Mean (±SE) blood glucose levels of Diannexin-treated and control recipients following transplantation of a marginal islet cell mass. * P<0.05 by the Mann-Whitney test.